The Neuberger Berman Disrupters ETF is an actively managed fund that seeks long-term capital appreciation. Launched in April 2022 and managed by Neuberger Berman, the strategy invests at least 80% of its assets in a concentrated portfolio of U.S. and foreign equity securities of companies pursuing "disruptive" growth agendas — businesses the managers view as upending existing markets or creating entirely new ones. Because it does not track a passive index, holdings and weights are determined by the portfolio managers.
The fund holds approximately 30 positions, with the top 10 accounting for nearly half of total assets, giving it meaningful single-name concentration. Assets under management (AUM), the total market value of the fund's portfolio, sit near $177 million, and the net expense ratio is 0.55%. The largest holdings are NVIDIA (NVDA), Advanced Micro Devices (AMD), Snowflake (SNOW), Shopify (SHOP), and Definium Therapeutics (DFTX). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
By sector, technology is the dominant allocation at roughly 49%, followed by healthcare at about 18%, industrials near 10%, and consumer cyclicals near 9%. Utilities, financials, and communication services round out the balance. Notable positions also include semiconductor-equipment maker ASML (ASML), power provider Constellation Energy (CEG), medtech firm Glaukos (GKOS), and chip designer Arm Holdings (ARM).
NBDS sits at the intersection of several structural technology themes. Semiconductors and semiconductor-equipment suppliers — a large share of the portfolio — are leveraged to artificial-intelligence capital spending and the build-out of data-center computing capacity. Cloud-data and software names such as Snowflake and Shopify reflect the ongoing shift of enterprise workloads and commerce to digital platforms.
The fund also carries a notable healthcare allocation, spanning clinical-stage biotech and medical-device companies. These positions introduce a different risk profile: rather than being driven primarily by the technology cycle, their performance can hinge on regulatory decisions and clinical trial outcomes. Meanwhile, a utility holding such as Constellation Energy links the portfolio to rising electricity demand tied to data centers and electrification.
The broader environment for these themes has been shaped by interest-rate expectations and investor appetite for long-duration, high-multiple growth equities. When risk sentiment cools, richly valued disrupters tend to face proportionally larger valuation pressure than the broader market.
After climbing toward a recent high above $42 per share in early October, NBDS has trended lower, recently trading near $35. The fund is down roughly 10% over the trailing month and approximately 14% over the trailing three months, with the decline concentrated in its semiconductor and cloud-software holdings. From what I see, this pullback reflects a broader de-rating of growth equities rather than a single company-specific event.
High-multiple technology names — including several of the fund's largest positions — have faced headwinds as investors reassessed valuations against the interest-rate backdrop. The portfolio's concentration amplifies this effect: because a handful of semiconductor and software positions drive a large share of returns, sector-wide weakness translates directly into fund-level declines. Healthcare holdings have provided some diversification, but their lower weightings have not fully offset technology-led weakness. The fund's exposure to power and electrification through Constellation Energy has been a secondary, more defensive theme within an otherwise growth-oriented book.
Several structural factors are likely to influence NBDS through 2026. Interest-rate expectations remain central: because the fund holds long-duration growth equities, falling rates or improving risk appetite could support valuations, while persistently restrictive policy or renewed inflation concerns could extend the recent de-rating.
The semiconductor cycle and the pace of AI-related capital expenditure will be important for the fund's largest positions, while cloud-software demand and enterprise spending trends will shape the software sleeve. In healthcare, clinical and regulatory milestones for biotech and medtech holdings represent discrete catalysts and risks that can move individual positions sharply.
Concentration is a key structural consideration. With roughly 30 names and a technology-heavy tilt, the fund's returns can diverge materially from broad equity benchmarks in either direction. Capital flows into active thematic ETFs, competitive pressures from lower-cost technology funds, and the evolution of the data-center power theme are additional factors worth monitoring.
When evaluating concentrated strategies like NBDS, I often turn to Tickeron’s AI Screener to compare holdings against peers and identify comparable opportunities across sectors. It helps me apply filters for technical indicators, fundamentals, and AI-generated signals, which refines my perspective on how these themes might evolve. AI Screener has become a practical part of reviewing thematic ETFs without replacing my own judgment on valuation and risk.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NBDS moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend. In 29 of 30 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBDS as a result. In 63 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for NBDS turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
The 10-day moving average for NBDS crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBDS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for NBDS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NBDS's RSI Indicator exited the oversold zone, 17 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +8.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBDS advanced for three days, in 249 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
NBDS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows